2013-2015 Ariad Key Milestones/Upcoming Events
Key Milestones
2013 Q2
• May 7 – Q1 Results
• Every Monday (no end date) – Rx data on Iclusig
• May 15 - ASCO ‘113 Abstracts released (old Jan 2013 data)
• Jun 1 - ASCO !!! PLUS !!! current Ph I ‘113 results
• May/Jun E.U. Iclusig Approval/Europe Launch
• May/Jun – GIST Ph II starts (c-kit)
• May/Jun ‘113 Ph II (of I/II) expsn cohorts
• June 3 Investor Meeting 8:30AM
• Jun 20 Annual shareholder Meeting 10:00A
2013 Q3/Q4
• July 3 ESMO GIST (no preso here)
• July 29/Early Aug – Q2 Results
• Q3 ‘113 (pivotal) Registration trial begins
• Q3 SPIRIT UK ‘quick change’ trial starts 1000pts
• Sept 30 ESMO ‘113 Ph I/II update
• Nov – Q3 results
• mid-Nov ASH 2013 Abstracts released
• Q4 Full EPIC Enrollment
• Dec 7 - 10, 2013 ASH 2013 EPIC Trial first look?
2014/2015
• Feb 2014 – 2013 Q4 and 2013 fy Results
• EPIC Trial – for 1st Line Approval vs. Gleevec, 1st int analysis data lock Jun 2014, results Q3 2014
• 2014 Japan filing for approval
• 2014 GIST Trial data???
• Q2 AACR
• 4Q14 Iclusig Final data readout from EPIC Ph3 trial (1st-line CML)
• 2014/2015 Iclusig Data from Ph1/2 AML trial
• 2014/2015 Iclusig Data from Ph2 trial in squamous NSCLC
• 2015 Iclusig Approval in Japan
• 2015 1st Line Iclusig Approval
• 2015/2106 AP26113 Approval
Annual Presentations/Events
• Jan JPMorgan
• Feb - Citi
• Feb Leerink Swann
• Feb RBS
• Mar Cowens
• Mar Barclays
•
• May 14, 2013 Merrill Lynch BofA 1:00P
• May 20, 2013 UBS 8:30A
• May 30, 2013 Deutsche bdAccess 8:30A
• June 5, 2013 Jefferies 2013
• Jun 11, 2013 Goldman Preso
•
• Sept Rodman 2013
• Sept Stifel Nicolaus
• Sept Morgan Stanley
• Sept UBS?
• Sept Citi Biotech Day
• Oct Ariad Investor Day
• Nov Lazard
• Dec Deutcshe BIOFest?
Potential wildcards:
- At any time, announcements of new initiatives, exec and corp news
- Positive news on Bellicum, IPO, Rida, etc.
- New 4th molecule announcement
- Buyout? Related Biotech buyouts creating buyout frenzy
